Vysis PathVysion Cleared For Herceptin Labeling; Is Early Detection Next?
This article was originally published in The Gray Sheet
Executive Summary
Genentech's Herceptin revised labeling allows use of Abbott/Vysis' PathVysion FISH assay to select drug treatment, but declines to support the assay's utility for the general population
You may also be interested in...
Abbott/Vysis’ PathVysion HER-2 Assay Endorsed By Herceptin Panel Review
Genentech's Herceptin package insert to include use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test should address potential discrepancies in assay results compared with immunohistochemistry (IHC) tests, FDA's Oncologic Drugs Advisory Committee concluded
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.